Skip to content Skip to footer
Subscribe Now
NEWS

GSK to Acquire 35Pharma for $950M

Shots: GSK has entered into an agreement to acquire 35Pharma, incl. its asset HS235, expanding scalable growth opportunities within its Respiratory, Immunology & Inflammation portfolio As per the deal, GSK will acquire 100% of 35Pharma’s equity for $950M in cash, payable at closing HS235, a therapy targeting the activin receptor signalling pathway, has completed P-I…
5 days ago

Read more

VIEWPOINTS_Micki Hultquist_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

Shots:  AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines  Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE)  The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…
February 5, 2024

Read more

VIEWPOINTS_Eli Khankin_2023
VIEWPOINTS

Eli Khankin Shares Update on the P-III IMAGINE Study Protocol Published in American Journal of Transplantation

Shots: Eli spoke about the P-III IMAGINE study protocol evaluating Clazakizumab along with 6 articles by several experts published in the American Journal of Transplantation Eli then talked about Clazakizumab's potential mechanism of action currently under investigation The interview shows how CSL Behring works to develop and deliver innovative therapies for people living with conditions in…
August 31, 2023

Read more